Preeclampsia and breast cancer risk

被引:95
作者
Innes, KE [1 ]
Byers, TE [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA
关键词
breast cancer; preeclampsia; hormones; estrogens; androgens; insulin; growth factors; hCG; fetal origin;
D O I
10.1097/00001648-199911000-00013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Breast cancer is associated with endogenous hormone levels, but the exact relation and underlying mechanisms remain unclear. Data from several recent epidemiologic studies suggest that a woman who experiences preeclampsia in her own pregnancy, or who was herself born to a preeclamptic pregnancy, is at reduced risk for breast cancer later in life. This paper reviews the evidence fora connection between preeclampsia and breast cancer risk, and discusses the hormonal mechanisms that might explain this association. Preeclampsia is characterized by reduced levels of estrogens and insulin-like growth factor-1, and by elevated levels of progesterone, androgens, human chorionic gonadotropin, IGF-1 binding protein, corticotropin-releasing factor, cortisol, and insulin. These factors may act both individually and synergistically to decrease breast cancer risk. The occurrence of preeclampsia during a woman's pregnancy may reflect an underlying hormonal profile that both predisposes her to preeclampsia and reduces her risk for breast cancer. In addition, the major hormonal alterations associated with preeclampsia during gestation may have lasting effects on subsequent breast cancer:risk. Finally, the hormonal and nutritional environment of the womb, for which preeclampsia is a marker, may play an important role in programming lifelong risk for breast cancer in the female offspring.
引用
收藏
页码:722 / 732
页数:11
相关论文
共 81 条
[31]  
HELZLSOUER KJ, 1995, CANCER-AM CANCER SOC, V76, P2059, DOI 10.1002/1097-0142(19951115)76:10+<2059::AID-CNCR2820761325>3.0.CO
[32]  
2-1
[33]  
HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79
[34]  
IINO K, 1986, OBSTET GYNECOL, V68, P58
[35]   ENHANCEMENT OF PLASMA CORTICOTROPIN-RELEASING HORMONE IN PREGNANCY-INDUCED HYPERTENSION [J].
JESKE, W ;
SOSZYNSKI, P ;
LUKASZEWICZ, E ;
DEBSKI, R ;
LATOSZEWSKA, W ;
ROGOZINSKI, W ;
SNOCHOWSKA, H ;
ZGLICZYNSKI, S .
ACTA ENDOCRINOLOGICA, 1990, 122 (06) :711-714
[36]   SERUM-LIPOPROTEINS, INSULIN, AND URINARY PROSTANOID METABOLITES IN NORMAL AND HYPERTENSIVE PREGNANT-WOMEN [J].
KAAJA, R ;
TIKKANEN, MJ ;
VIINIKKA, L ;
YLIKORKALA, O .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (03) :353-356
[37]   THE ROLE OF ESTROGENS AND PROGESTAGENS IN THE EPIDEMIOLOGY AND PREVENTION OF BREAST-CANCER [J].
KEY, TJA ;
PIKE, MC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (01) :29-43
[38]   INSULIN-LIKE GROWTH FACTOR-I THERAPY IN DIABETES - PHYSIOLOGICAL-BASIS, CLINICAL BENEFITS, AND RISKS [J].
KOLACZYNSKI, JW ;
CARO, JF .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (01) :47-55
[39]   CORTICOTROPIN-RELEASING HORMONE IN MATERNAL AND CORD PLASMA IN PREECLAMPSIA [J].
LAATIKAINEN, T ;
VIRTANEN, T ;
KAAJA, R ;
SALMINENLAPPALAINEN, K .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1991, 39 (01) :19-24
[40]   DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues:: Its role during aging [J].
Labrie, F ;
Bélanger, A ;
Luu-The, V ;
Labrie, C ;
Simard, J ;
Cusan, L ;
Gomez, JL ;
Candas, B .
STEROIDS, 1998, 63 (5-6) :322-328